Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer’s Disease

Posted by & filed under News.

First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer’s Disease Research Unit and Yale PET Center PITTSBURGH, June 18, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today announced that patient dosing has begun in the SPARC (Synaptic Protection for Alzheimer’s Restoration… Read more »

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting

Posted by & filed under News.

Pittsburgh, March 14, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the company’s co-founder and chief science officer, Dr. Susan Catalano, is presenting Phase 1b/2a results demonstrating the unique synaptoprotective mechanism of action… Read more »

Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate

Posted by & filed under News.

PITTSBURGH, July 19, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative small molecule therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today presented results of an open-label Phase 1 study of Cognition’s lead clinical candidate, CT1812. In this study, which was presented at the… Read more »